Broad evidence of xylazine in the UK illicit drug market beyond heroin supplies: Triangulating from toxicology, drug-testing and law enforcement

C. S. COPELAND ; K. RICE ; K. L. ROCK ; S. HUDSON ; P. STREETE ; A. J. LAWSON ; L. COUCHMAN ; A. HOLLAND ; S. MORLEY | 2024
Dans Addiction (Vol.119, n°7, July 2024) Article : Périodique

BACKGROUND AND AIMS: Xylazine is a non-opioid sedative which has spread rapidly throughout the US illicit drug supply. This study aimed to describe the spread of xylazine throughout the UK illicit drug supply. METHODS: Xylazine detections in h[...]

Plus d'info

Ajouter à la sélection

Lien externe

A deadly trend in fentanyl fatalities (England, 1998-2017)

H. CLARIDGE ; B. D. WILLIAMS ; C. S. COPELAND | 2020
Dans British Journal of Clinical Pharmacology (Vol.86, n°3, March 2020) Article : Périodique

Aim: To identify trends in drug-related deaths associated with fentanyl and its derivatives, including novel variants, in England, 1998-2017. Methods: Case reports from the National Programme on Substance Abuse Deaths (NPSAD) where a pharmaceut[...]

Plus d'info

Ajouter à la sélection

Nouveauté

Legislating novel psychoactive substances: lessons from 15 years of UK mortality data (2007-2022)

K. L. ROCK ; R. TREBLE ; C. S. COPELAND | 2025
Dans Frontiers in Pharmacology (Vol.16, 2025) Article : Périodique

Background: Novel Psychoactive Substances (NPS) emerged in the early 2000s as chemically designed alternatives to circumvent laws which internationally control drugs. There is limited evidence that NPS are produced in the UK, whereas China has l[...]

Plus d'info

Ajouter à la sélection

Lien externe